Used in AKCEA-TTR-LRx, a GalNac-ASO also designed to inhibit production of TTR, this technology is now being tested in phase three clinical trial in patients with polyneuropathy caused by hereditary TTR amyloidosis with positive results (Table 2). Here, TTR is linked to familial amyloid neuropathy.